InVentiv Health acquires Ignite Health and Chamberlain Healthcare Public Relations

Share this article:
InVentiv Health today announced two major acquisitions worth over $30 million to its communications group. InVentiv Health will acquire Ignite Health for $20 million in cash and stock, plus potential earn-out payments for exceeding specified financial targets. Based in Irvine, CA, Ignite Health specializes in technology-driven medical advertising and interactive communications targeting patients, caregivers and healthcare professionals. Ignite Health clients include Amylin Pharmaceuticals, Bausch & Lomb, Cephalon, Eli Lilly, Genomic Health, Gilead Health, Merck Publishing, Novacea and Valeant Pharmaceuticals. “Joining with inVentiv Health will enable us to maintain our focus, while also providing us with access to a broader range of talent and resources that will allow us to better serve our clients,” Ignite Health CEO Jackie Herr said in a statement. Herr will continue to lead Ignite following the acquisition and no staffing changes are planned, inVentiv Health spokeswoman Marcia Frederick told MM&M. “Nothing with their business will change aside from the fact that they now have our resources to tap into and likewise, we now have their resources to tap into,” Frederick said. InVentiv also announced plans to acquire the healthcare focused public relations firm Chamberlain Communications Group for $13 million in cash and stock, plus potential earn-out payments for exceeding specified financial targets. New York-based Chamberlain was founded in 1993 and serves the healthcare industry exclusively. “Our focus has always been building on strong, healthy brands through campaigns that provide doctors and patients with powerful, evidence-based rationales for public healthcare decisions,” said Richard Chamberlain, president of Chamberlain Healthcare Public Relations in a statement. “We are joining inVentiv Health because they share this philosophy.” Chamberlain will continue to lead the business from its existing New York offices. No staffing changes are planned, Frederick said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...